Mark Bodmer is the Chief Executive Officer at Nucleome Therapeutics, a biotechnology company that utilizes 3D genomics to discover precision medicines.
Mark Bodmer is the Chief Executive Officer at Nucleome Therapeutics, a biotechnology company that utilizes 3D genomics to discover precision medicines for complex diseases. He joined the company from Evelo Biosciences, where he served as Chief Scientific Officer and President of R&D since 2016. Bodmer holds a PhD in Genetics from the University of Cambridge.
Full founder directory · Investor directory · Company funding database · Fundraising library